🇺🇸 FDA
Patent

US 10730941

Antigen-binding proteins targeting CD56 and uses thereof

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 10730941 (Antigen-binding proteins targeting CD56 and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/48